GlassScriptPhysician profile
Kathy C Chu
NPI 1659314656
$6,868.92
in general payments reported to CMS, 2019-2025
36 companies · $28.14 in 2025
The $28.14 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $348 · 2021: $1,752 · 2022: $1,722 · 2023: $1,469 · 2024: $967 · 2025: $28.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,276.53 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $901.57 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $802.57 | 2019-2024 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $536.85 | 2019-2024 | |
| Pfizer INC. | $408.01 | 2019-2024 | |
| Astellas Pharma US INC | $404.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $328.30 | 2020-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $314.47 | 2020-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $231.38 | 2021-2024 | Mounjaro |
| Esperion Therapeutics, INC. | $194.79 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $155.62 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $135.25 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $130.91 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $121.30 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.60 | 2021-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.